| Uptake of 153Sm-DTPA-bis-biotin and 99mTc-DTPA-bis-biotin in rat as-30D-hepatoma cells. | |
| | |
MedLine Citation:
|
PMID: 12623112 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Labeled biotin has been used mainly for pretargeted therapy, an approach for increasing the amount of radioactivity delivered to a cancer cell. The aim of this investigation was to prepare (153)Sm-DTPA-bis-biotin and (99m)Tc-DTPA-bis-biotin in order to study their in vitro and in vivo uptake in rat AS-30D hepatoma cells found in ascites and in implanted tumor. DTPA-bis-biotin (pH 8) was (153)Sm labeled with (153)SmCl(3) and (99m)Tc-DTPA-bis-biotin was prepared via SnCl(2) reduction. Radiochemical purity was >98% in both cases. AS-30D hepatoma cells were obtained from ascites of a rat with hepatoma and were propagated in the peritoneum cavity of normal rats. In vitro ascites cell (153)Sm-DTPA-bis-biotin uptake was compared with (153)SmCl(3) cell uptake. The ratio cell (153)Sm-DTPA-bis-biotin/(153) SmCl(3) was 39.6 and when avidin was added it increased to 50. The ratio (99m)Tc-DTPA-bis-biotin/TcO(4)Na was 8.7. Concentration of (153)Sm-DTPA-bis-biotin in tumor 2, 3 and 24 h after administration, was 5, 15 and 3 times higher than in normal muscle (T/nT). Biodistribution in a 0.083-24 h time period showed that (153)Sm-DTPA-bis-biotin was taken up only by ascites tumor cells and hepatoma cells. Two and 3 h ratio ascites/liver (As/Lv) was 6.4 and 6.0. For (99m)Tc-DTPA-bis-biotin 2 and 3 h T/nT was 15.7 and 4.7 and 2 h As/Lv was 1.4. In conclusion, both radiopharmaceuticals show high uptake in rat AS-30D hepatoma cells in ascites and in implanted tumor. Since lung, thyroid, kidney, liver or pancreas carcinomas are ascites producing cancers (153)Sm-DTPA-bis-biotin would be an adequate therapeutic radiopharmaceutical for these patients whose life quality would be enhanced with control of ascites, and a reduction of the primary tumor and its metastases. |
| | |
Authors:
|
Luis Correa-González; Consuelo Arteaga de Murphy; Guillermina Ferro-Flores; Martha Pedraza-López; Eduardo Murphy-Stack; Dolores Mino-León; Graciela Pérez-Villaseñor; Yaneth Díaz-Torres; Rodrigo Muñóz-Olvera |
Publication Detail:
|
Type: Comparative Study; Evaluation Studies; Journal Article |
Journal Detail:
|
Title: Nuclear medicine and biology Volume: 30 ISSN: 0969-8051 ISO Abbreviation: Nucl. Med. Biol. Publication Date: 2003 Feb |
Date Detail:
|
Created Date: 2003-03-07 Completed Date: 2003-10-27 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9304420 Medline TA: Nucl Med Biol Country: England |
Other Details:
|
Languages: eng Pagination: 135-40 Citation Subset: IM |
Affiliation:
|
Servicio de Medicina Nuclear, Hospital de Especialidades, Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Mexico. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Biotin / analogs & derivatives*, diagnostic use*, pharmacokinetics* Carcinoma, Hepatocellular / metabolism*, pathology, radionuclide imaging* Female Liver Neoplasms / metabolism, pathology, radionuclide imaging Neoplasm Transplantation Organ Specificity Organotechnetium Compounds / diagnostic use*, pharmacokinetics* Pentetic Acid / analogs & derivatives*, diagnostic use*, pharmacokinetics* Radiopharmaceuticals / chemical synthesis, diagnostic use, pharmacokinetics Rats Rats, Wistar Reference Values Tissue Distribution Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/DTPA-bis-biotin; 0/Organotechnetium Compounds; 0/Radiopharmaceuticals; 0/technetium 99m DTPA-bisbiotin; 58-85-5/Biotin; 67-43-6/Pentetic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 99mTc-labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal m...
Next Document: In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA ...